Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liposarcoma × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 6 Carcinoma, Transitional Cell 5 Acrocephalosyndactylia 5 Neoplasm Metastasis 3 Gastrointestinal Neoplasms 3 Breast Neoplasms 3 Recurrence 2 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Miscellaneous 1 Solid Tumor 1 Sarcoma 1 Oligodendroglioma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Myeloproliferative Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Locally Advanced Unresectable Gastric Cancer 1 Liposarcoma 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1

Interventions

Doxorubicin 6 Trabectedin 5 pazopanib 4 Radiotherapy 4 ribociclib 3 pembrolizumab 3 palbociclib 3 Gemcitabine 3 brostallicin 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Radiation 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Immunoglobulin G 2 Imatinib Mesylate 2 Ifosfamide 2 Docetaxel 2 Dexamethasone 2 CTLA-4 Antigen 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 tanespimycin 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 sitravatinib 1 saracatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06389799 2025-08-28

PERELI

Lund University Hospital

Phase 2 Recruiting

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡